Replies to post #198685 on Biotech Values

[DewDiligence]

ABBV/ENTA’s Global Phase-3 Program for ABT-493/ABT-530

ENDURANCE-1—TN non-cirrhotic GT1; 600 patients; 8- and 12-week arms; expected completion Jan 2017: https://www.clinicaltrials.gov/ct2/show/study/NCT02604017

ENDURANCE-2—TN/TE non-cirrhotic GT2; 321 patients; 12-week arms (delayed-start control arm for safety comparison); expected completion Dec 2016:
https://www.clinicaltrials.gov/ct2/show/NCT02640482

ENDURANCE-3—TN non-cirrhotic GT3; 345 patients; 12-week arms (ABT-493/ABT-530 head-to-head vs Sovaldi/Daklinza); expected completion Dec 2016:
https://www.clinicaltrials.gov/ct2/show/NCT02640157

ENDURANCE-4—TN/TE non-cirrhotic GT4/GT5/GT6; 130 patients; single 12-week arm; expected completion Jun 2016:
https://www.clinicaltrials.gov/ct2/show/NCT02636595

EXPEDITION-1—TN/TE cirrhotic GT1/GT2/GT4/GT5/GT6; 175 patients; single 12-week arm; expected completion Sep 2016:
https://www.clinicaltrials.gov/ct2/show/NCT02642432

--
TN=treatment-naïve
TE=treatment-experienced